AA
CTMX icon

AlphaCentric Advisors’s CytomX Therapeutics CTMX Stock Holding History

AlphaCentric Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-257,500
Closed -$373K – 176
2022
Q3 		$373K Buy
+257,500
New +$396K 0.38% 69

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AlphaCentric Advisors's CTMX Position: Q4 2022 in Review

AlphaCentric Advisors sold out of CytomX Therapeutics (CTMX) in Q4 2022, closing a stake of 257,500 shares — an estimated $373K sold.

AlphaCentric Advisors first reported a position in CTMX in Q3 2022 and held it in 1 quarter. The position peaked at $373K in Q3 2022. 81 funds tracked by Wall St. Rank hold CTMX as of Q4 2022.

  • AlphaCentric Advisors reported no remaining CytomX Therapeutics position as of Q4 2022 after selling out during the quarter.
  • AlphaCentric Advisors sold 257,500 CytomX Therapeutics shares in Q4 2022, an estimated $373K.
  • AlphaCentric Advisors first reported a position in CytomX Therapeutics in Q3 2022 and held it in 1 quarter.
  • AlphaCentric Advisors's CytomX Therapeutics position peaked at $373K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2022.

Based on AlphaCentric Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.